Moderna Stock Surges Over 170% YTD but Faces Analyst Skepticism
In the first half of 2026, Moderna Inc. (NASDAQ:MRNA) has seen its stock price surge over 170%, driven by strong Q1 revenue growth and a renewed focus on oncology trials and vaccine development. First-quarter revenue reached $389 million in 2026, up from $108 million the previous year, with net product sales rising to $352 million—a 309% increase. Despite these gains, Moderna reported a GAAP net loss of $1.3 billion due largely to legal costs and settlements. Analysts remain divided on the stock's future performance. While Piper Sandler raised its price target from $69 to $77 citing recent data updates and events like Science Day, most analysts still maintain 'Hold' ratings with a wide range of targets between $18-25 and up to nearly $77. The uncertainty is compounded by the fact that many key pipeline assets won't yield results until 2028 or later. Insider activity also reflects mixed signals: while some hedge funds increased their holdings, Susquehanna cut its stake significantly in Q1 2026 and Moderna President Stephen Hoge executed a large stock sale at elevated prices.
Tickers: $MRNA
Topics: biotech mRNA technology regulatory review stock performance